These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3001233)

  • 1. Effect of naltrexone on senile dementia of the Alzheimer type.
    Hyman BT; Eslinger PJ; Damasio AR
    J Neurol Neurosurg Psychiatry; 1985 Nov; 48(11):1169-71. PubMed ID: 3001233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naltrexone and Alzheimer's disease.
    Serby M; Resnick R; Jordan B; Adler J; Corwin J; Rotrosen JP
    Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):587-90. PubMed ID: 3541052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nontolerance to the opioid antagonism of naltrexone.
    Kleber HD; Kosten TR; Gaspari J; Topazian M
    Biol Psychiatry; 1985 Jan; 20(1):66-72. PubMed ID: 2981129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of naltrexone in the treatment of schizophrenia.
    Gitlin MJ; Gerner RH; Rosenblatt M
    Psychopharmacology (Berl); 1981; 74(1):51-3. PubMed ID: 6791204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral physostigmine treatment for patients with presenile and senile dementia of the Alzheimer's type: a double-blind placebo-controlled trial.
    Jenike MA; Albert MS; Heller H; Gunther J; Goff D
    J Clin Psychiatry; 1990 Jan; 51(1):3-7. PubMed ID: 2403997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of narcotic antagonists in the rehabilitation of opiate addicts: a review of naltrexone.
    Schecter A
    Am J Drug Alcohol Abuse; 1980; 7(1):1-18. PubMed ID: 6254356
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple, single-dose naltrexone administrations fail to effect overall cognitive functioning and plasma cortisol in individuals with probable Alzheimer's disease.
    Pomara N; Roberts R; Rhiew HB; Stanley M; Gershon S
    Neurobiol Aging; 1985; 6(3):233-6. PubMed ID: 3903533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of naltrexone, a long-acting opiate antagonist.
    Crabtree BL
    Clin Pharm; 1984; 3(3):273-80. PubMed ID: 6329589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial of naltrexone in premenstrual syndrome.
    Chuong CJ; Coulam CB; Bergstralh EJ; O'Fallon WM; Steinmetz GI
    Obstet Gynecol; 1988 Sep; 72(3 Pt 1):332-6. PubMed ID: 3043289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of naloxone in senile dementia: a double-blind trial.
    Reisberg B; Ferris SH; Anand R; Mir P; Geibel V; De Leon MJ; Roberts E
    N Engl J Med; 1983 Mar; 308(12):721-2. PubMed ID: 6338389
    [No Abstract]   [Full Text] [Related]  

  • 11. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease.
    Little A; Levy R; Chuaqui-Kidd P; Hand D
    J Neurol Neurosurg Psychiatry; 1985 Aug; 48(8):736-42. PubMed ID: 3897460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of pruritus with topically applied opiate receptor antagonist.
    Bigliardi PL; Stammer H; Jost G; Rufli T; Büchner S; Bigliardi-Qi M
    J Am Acad Dermatol; 2007 Jun; 56(6):979-88. PubMed ID: 17320241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Naltrexone attenuates self-injurious behavior in mentally retarded subjects.
    Kars H; Broekema W; Glaudemans-van Gelderen I; Verhoeven WM; van Ree JM
    Biol Psychiatry; 1990 Apr; 27(7):741-6. PubMed ID: 2158355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Action of naloxone and naltrexone in different types of psychoses.
    Volavka J
    Mod Probl Pharmacopsychiatry; 1981; 17():202-12. PubMed ID: 6276726
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of the cortisol response to naltrexone in Alzheimer's disease.
    Pomara N; Stanley M; Rhiew HB; Bagne CA; Deptula D; Galloway MP; Tanimoto K; Verebey K; Tamminga CA
    Biol Psychiatry; 1988 Apr; 23(7):726-33. PubMed ID: 3285899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter trial of naloxone in Alzheimer's disease.
    Henderson VW; Roberts E; Wimer C; Bardolph EL; Chui HC; Damasio AR; Eslinger PJ; Folstein MF; Schneider LS; Teng EL
    Ann Neurol; 1989 Apr; 25(4):404-6. PubMed ID: 2653175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic efficacy of pyritinol in patients with senile dementia of the Alzheimer type (SDAT) and multi-infarct dementia (MID).
    Fischhof PK; Saletu B; Rüther E; Litschauer G; Möslinger-Gehmayr R; Herrmann WM
    Neuropsychobiology; 1992; 26(1-2):65-70. PubMed ID: 1475039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Senile dementia of the Alzheimer type treated with aniracetam: a new nootropic agent.
    Sourander LB; Portin R; Mölsä P; Lahdes A; Rinne UK
    Psychopharmacology (Berl); 1987; 91(1):90-5. PubMed ID: 3103163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No effect from double-blind trial of physostigmine and lecithin in Alzheimer disease.
    Wettstein A
    Ann Neurol; 1983 Feb; 13(2):210-2. PubMed ID: 6830183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.